News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Daily News Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists Todd Neale July 09, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Daily News Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA Michael O'Riordan April 26, 2021
News Daily News Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms Michael O'Riordan April 02, 2021
News Daily News Despite COVID-19, Heart Disease Remains Top US Killer: AHA Michael O'Riordan January 28, 2021